Metabolomic biomarkers across plasma, serum, and ocular fluids in age-related macular degeneration: narrative review and evidence synthesis.

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss globally. It is a degenerative disorder characterized by progressive macular damage and systemic metabolic dysregulation. Metabolomics elucidates relationships between metabolic alterations and disease phenotypes, providing scientific foundation for biomarker-driven predictive diagnostics. Current AMD staging predominantly relies on a linear classification based on clinical symptoms and imaging phenotypes. But metabolic alterations often precede morphological changes, providing a crucial window for early screening and intervention. Recent multi-biofluid metabolomic studies have identified key metabolic biomarkers, including glycerophospholipid pathway metabolites, acylcarnitines, branched-chain amino acids, and adenosine. They are predictive of transition from non-advanced to advanced stages. This review summarizes stage-specific metabolic biomarkers across AMD progression, such as 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0-20:4 PC), sphingosylphosphorylcholine (LysoSM[d18:1]), lysophosphatidylcholine (LysoPC[18:4]), short-chain acylcarnitines (e.g., acetylcarnitine [C2]), long-chain acylcarnitines (e.g., linoleoylcarnitine [C18:2]), and valerylcarnitine (C5). These biomarkers may allow for timely intervention before irreversible visual impairment and underscore the importance of differential metabolic signatures between stable and progressive stages for early disease management. By unveiling the dynamic changes of these critical metabolites, and providing evidence for their prognostic value in stage transition, this review proposes an evidence-based foundation for early risk stratification and precision intervention in AMD.